Randomized trial evaluating the role of weight loss in overweight and obese men with early stage prostate Cancer on active surveillance: Rationale and design of the Prostate Cancer Active Lifestyle Study (PALS).
Aged
Humans
Male
Middle Aged
Blood Glucose
Body Mass Index
Diet
Exercise
Healthy Lifestyle
Neoplasm Grading
Obesity
/ epidemiology
Overweight
/ epidemiology
Prostatic Neoplasms
/ epidemiology
Quality of Life
Randomized Controlled Trials as Topic
Research Design
Watchful Waiting
Weight Reduction Programs
/ methods
Clinical Trials, Phase III as Topic
Active surveillance
Diet
Exercise
Glucose regulation
Insulin regulation
Nutrition
Outcomes
Physical activity
Prostate cancer
Randomized trial
Journal
Contemporary clinical trials
ISSN: 1559-2030
Titre abrégé: Contemp Clin Trials
Pays: United States
ID NLM: 101242342
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
23
01
2019
revised:
26
03
2019
accepted:
04
04
2019
pubmed:
20
4
2019
medline:
4
9
2020
entrez:
20
4
2019
Statut:
ppublish
Résumé
Active surveillance (AS) is increasingly used to monitor patients with low-risk prostate cancer; however, approximately 50% of AS patients experience disease reclassification requiring definitive treatment and little is known about patient characteristics that modify the risk of reclassification. Obesity may be one of the major contributing factors. The Prostate Cancer Active Lifestyle Study (PALS) is a clinical trial evaluating the impact of weight loss among overweight/obese (Body Mass Index (BMI) ≥ 25 kg/m
Identifiants
pubmed: 31002955
pii: S1551-7144(19)30048-5
doi: 10.1016/j.cct.2019.04.004
pmc: PMC6527481
mid: NIHMS1527760
pii:
doi:
Substances chimiques
Blood Glucose
0
Types de publication
Clinical Trial Protocol
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
34-39Subventions
Organisme : NCI NIH HHS
ID : P30 CA015704
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA184075
Pays : United States
Organisme : NCI NIH HHS
ID : R50 CA221836
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2019 Elsevier Inc. All rights reserved.
Références
Diabetes Care. 1999 Apr;22(4):623-34
pubmed: 10189543
Urology. 2000 Dec 20;56(6):899-905
pubmed: 11113727
N Engl J Med. 2002 Feb 7;346(6):393-403
pubmed: 11832527
Diabetes Care. 2002 Dec;25(12):2165-71
pubmed: 12453955
N Engl J Med. 2003 Apr 24;348(17):1625-38
pubmed: 12711737
Int J Obes (Lond). 2005 Oct;29(10):1153-67
pubmed: 15997250
J Urol. 2005 Sep;174(3):1065-9; discussion 1069-70
pubmed: 16094059
Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6889-94
pubmed: 16203779
Eur J Cancer. 2005 Dec;41(18):2887-95
pubmed: 16243513
Psychosomatics. 2006 Jul-Aug;47(4):340-7
pubmed: 16844894
J Gerontol A Biol Sci Med Sci. 2006 Oct;61(10):1075-81
pubmed: 17077202
Cancer. 2007 Feb 15;109(4):675-84
pubmed: 17211863
Cancer. 2007 Mar 15;109(6):1192-202
pubmed: 17311344
Cancer Epidemiol Biomarkers Prev. 2007 Oct;16(10):2150-4
pubmed: 17932364
Prostate. 2008 Jan 1;68(1):11-9
pubmed: 17999389
J Natl Cancer Inst. 2007 Dec 5;99(23):1793-800
pubmed: 18042933
Mol Carcinog. 2008 Jun;47(6):458-65
pubmed: 18058807
Prostate. 2008 Feb 15;68(3):321-35
pubmed: 18175332
Diabetes Care. 2008 Jul;31(7):1416-21
pubmed: 18356403
Cancer Res. 2008 Apr 15;68(8):3066-73
pubmed: 18413778
Proc Natl Acad Sci U S A. 2008 Jun 17;105(24):8369-74
pubmed: 18559852
Prostate. 2009 Jan 1;69(1):33-40
pubmed: 18785179
Lancet Oncol. 2008 Nov;9(11):1039-47
pubmed: 18835745
Nat Rev Cancer. 2008 Dec;8(12):915-28
pubmed: 19029956
Prostate. 2009 Jun 1;69(8):820-6
pubmed: 19189299
Cancer Prev Res (Phila). 2009 Jun;2(6):557-65
pubmed: 19470786
J Urol. 2009 Aug;182(2):491-6; discussion 496-8
pubmed: 19524974
Cancer. 2009 Nov 15;115(22):5263-71
pubmed: 19670453
Lancet. 2009 Nov 14;374(9702):1677-86
pubmed: 19878986
Cancer Prev Res (Phila). 2010 Mar;3(3):279-89
pubmed: 20179296
Urology. 2010 Sep;76(3):695-700
pubmed: 20394969
Prostate. 2010 Oct 1;70(14):1540-6
pubmed: 20687228
Qual Life Res. 2011 Dec;20(10):1727-36
pubmed: 21479777
Eur Urol. 2012 Feb;61(2):356-62
pubmed: 21803484
Cancer Prev Res (Phila). 2011 Dec;4(12):2062-71
pubmed: 22027686
Ann Intern Med. 2012 Apr 17;156(8):591-5
pubmed: 22351514
Eur Urol. 2012 Dec;62(6):976-83
pubmed: 22698574
Eur Urol. 2013 May;63(5):800-9
pubmed: 23219374
Prostate Cancer Prostatic Dis. 2013 Jun;16(2):204-8
pubmed: 23459096
Cancer. 2013 Nov 15;119(22):3992-4002
pubmed: 24006289
J Surg Oncol. 2014 Jun;109(8):830-5
pubmed: 24610744
Eur Urol. 2014 Nov;66(5):841-8
pubmed: 24954793
Urol Oncol. 2015 May;33(5):201.e1-8
pubmed: 25791753
Prostate. 2015 Nov;75(15):1694-703
pubmed: 26201966
J Urol. 2017 Apr;197(4):1026-1033
pubmed: 27810448
BJU Int. 2018 Apr;121(4):534-539
pubmed: 28437029
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
J Natl Cancer Inst. 1997 Mar 5;89(5):385-9
pubmed: 9060961